HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

PRINCIPLESOF CHOICEH. PYLORIFIRST-LINE THERAPY: CURRENT STATE OF PROBLEM

Download full text PDF
Issue: 
9
Year: 
2015

Professor A. Svistunov (1), MD; Professor M. Osadchuk (1), MD; Professor A. Osadchuk (2), MD 1 -I.M. Sechenov First Moscow State Medical University 2 -Samara State Medical University

The purpose of the review. Presentat the present levelprinciples of choice offirst-line regimensfor eradication of Helicobacter pylori. Show ingepidemiological aspects of H. pylori resistance to antibiotics, included in the first linecircuit. On the basis of evidence presented various schemes of eradication, taking in to account the nature of the antimicrobialresistant, and the degreeofefficiency of elimination H. pylori. High lightspromisingways of improvingantimicrobial therapy H. pylori-infection.

Keywords: 
Helicobacter pylori
eradication therapy



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Baryshnikova N.V., Denisova E.V., Kornienko E.A. i dr. Epidemiologicheskoe issledovanie rezistentnosti Helicobacter pylori k klaritromitsinu u zhitelej Sankt-Peterburga s jazvennoj bolezn'ju // Eksper. i klin. gastroenterol. – 2009; 5: 73–6.
  2. Isaeva G.Sh. Rezistentnost' Hp k antibakterial'nym preparatam i metody ee opredelenija // Klin. mikrobiol. antimikrob. himioter. – 2010; 12 (1): 57–66.
  3. Kudrjavtseva L.V. Sostojanie antibiotikorezistentnosti Helicobacter pylori v Rossii // Eksper. i klin. gastroenterol. – 2003; 3: 4–5.
  4. Kucherjavyj Ju.A., Andreev D.N., Barkalova E.V. Kliniko-molekuljarnye aspekty rezistentnosti Helicobacter pylori k antibakterial'nym preparatam // Med. sovet. – 2013; 10: 11–5.
  5. Maev I.V., Kucherjavyj Ju.A., Andreev D.N. Aktual'nye vozmozhnosti optimizatsii antihelikobakternoj terapii // Lechaschij vrach. – 2014; 4: 73–9.
  6. Maev I.V., Kucherjavyj Ju.A., Andreev D.N. Antibiotikorezistentnost' Helicobacter pylori: ot klinicheskogo znachenija do molekuljarnyh mehanizmov // Lechaschij vrach. – 2014; 2: 34–40.
  7. Maev I.V., Kucherjavyj Ju.A., Oganesjan T.S. i dr. Kakie shemy lechenija infektsii Helicobacter pylori nuzhny nam segodnja? // Farmateka. – 2011; 11: 24–9.
  8. Samsonov A.A., Andreev D.N., Grechushnikov V.B. i dr. Rezistentnost' Helicobacter pylori k komponentam eradikatsionnoj terapii i puti ee preodolenija // Farmateka. – 2015; 2: 26–30.
  9. Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? // Ther. Adv. Gastroenterol. – 2011; 4: 103–14.
  10. Cardarolli S., Rolfo A., Todros T. Helicobacter pylori and pregnancy-related disoders // World J. Gastroenterol. – 2014; 20 (3): 654–64.
  11. Cetinkaya Z., Sezikli M., Güzelbulut F. et al. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin // Helicobacter. – 2010; 15 (2): 143–7.
  12. Chey W., Wong B. American College of Gastroenterology guideline on the management of Helicobacter pylori infection // Am. J. Gastroenterol. – 2007; 102: 1808–25.
  13. Every A. Key host pathogen interactions for designing novel interventions against Helicobacter pylori // Trends Microbiol. – 2013; 21: 253–9.
  14. Federico A., Gravina A., Miranda A. et al. Eradication of Helicobacter pylori infection: Which regimen first? // World J. Gastroenterol. – 2014; 20 (3): 665–72.
  15. Federico A., Nardone G., Gravina A. et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection // Gastroenterology. – 2012; 143: 55–61.
  16. Fischbach L., Evans E. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori // Aliment. Pharmacol. Ther. – 2007; 26 (3): 343–57.
  17. Gatta L., Vakil N., Vaira D. et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequence therapy // BMG. – 2013; 7 (347): 4587.
  18. Gill S., O’Brien L., Einarson T. et al. The safety of proton pump inhibitors (PPI) in pregnancy: a meta-analysis // Am. J. Gastroenterol. – 2009; 104: 1541–5.
  19. Gisbert J., Calvel X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori // Clin. Exp. Gastroenterol. – 2012; 5: 23–34.
  20. Gisbert J., Perez-Aisa A., Castro-Femandez M. et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin // Dig. Liver Dis. – 2010; 42 (287): 90.
  21. Graham D., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance // Gut. – 2010; 59 (8): 1143–53.
  22. Kim S., Lee S., Hyun J. et al. Comparative study of Helicobacter pylorieradication rates with 5-day quadruple «concominant» therapy and 7-day standard triple therapy // J. Clin. Gastroenterol. – 2013; 47: 21–4.
  23. Liang J., Li J., Han Y. et al. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial // Helicobacter. – 2012; 17 (6): 458–65.
  24. Liou J., Chang C., Chen M. et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study // PLoS One. – 2015; 10 (5): 0124199.
  25. Mahadevan U. Gastrointestinal medications in pregnancy // Best Pract. Res. Clin. Gastroenterol. – 2007; 21: 849–77.
  26. Malfertheiner P., Bazzoli F., Delchier J. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, methronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial // Lancet. – 2011; 377: 905–13.
  27. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007; 56 (6): 772–81.
  28. Malfertheiner P., Megraud F., O'Morain C. et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report // Gut. – 2012; 61 (5): 646–64.
  29. Megraud F. Hp antibiotic resistance: prevalence, importance, and advances in testing // Gut. – 2004; 53: 1374–84.
  30. Megraud F. Antimicrobial Resistance and Approaches to Treatment. In: P. Sutton, H. Mitchell eds. Helicobacter pylori in the 21st Century / Wallingford, UK: CABI, 2010.
  31. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. – 2013; 62 (1): 34–42.
  32. Molina-Infante J., Romano M., Fernadez-Bermejo M. et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with rates of antibiotic resistance // Gastroenterology. – 2013; 145: 121–8.
  33. Nishizawa T., Nishizawa Y., Yahagi N. et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis // J. Gastroenterol. Hepatol. – 2014; 29 (4): 20–4.
  34. Perna F., Zullo A., Ricci C. et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance // Dig. Liver Dis. – 2007; 39 (11): 1001–5.
  35. Polat Z., Kadayaifci A., Kantarcioglu M. et al. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori // Eur. J. Intern. Med. – 2012; 23: 165–8.
  36. Riahizadeh S., Malekzadeh R., Agah S. et al. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared or clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial // Helicobacter. – 2010; 15: 497–504.
  37. Romano M., Cuano A., Gravina A. et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial // Gut. – 2010; 59: 1465–70.
  38. Sardarian H., Fakheri H., Hosseini V. et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial // Helicobacter. – 2013; 18 (2): 129–34.
  39. Smith S., O’Morain C., McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance // World J. Gastroenterol. – 2014; 20 (29): 9912–21.
  40. Sun Q., Liang X., Zheng Q. et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple for initial Helicobacter pylori eradication // Helicobacter. – 2010; 15 (3): 233–8.
  41. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther. – 2010; 32: 1069–79.
  42. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium containing probiolic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. – 2013; 47: 25–32.
  43. Zhang Y., Xia H., Zhuang Z. et al. Review article: «true» re-infection of Helicobacter pylori after successful eradication-worldwide annual rates, risk factors and clinical implication // Aliment. Pharmacol. Ther. – 2009; 29: 145–60.